Cited by 830Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, Lecia V., Martins, Renato G., Spigel, David, Grunberg, Steven M., Spira, Alexander, Jänne, Pasi A., Joshi, Victoria A., McCollum, David, Evans, Tracey L., Muzikansky, Alona, Kuhlmann, Georgiana L., Han, Moon, Goldberg, Jonathan S., Settleman, Jeffrey, Iafrate, A. John, Engelman, Jeffrey A., Haber, Daniel A., Johnson, Bruce E., Lynch, Thomas J.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.8494

Open this paper in CoChat — free account

Abstract

PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms. PATIENTS AND METHODS: Chemotherapy-naïve patients with advanced NSCLC with >or= 1 clinical characteristic associated with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21. Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity. The primary outcome was response rate. RESULTS: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%). EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21% of mutation-positive cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q. Thirty-one patients received gefitinib. The response rate was 55% (95% CI, 33 to 70) and median progression-free survival was 9.2 months (95% CI, 6.2 to 11.8). Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis. Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification. CONCLUSION: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance. This strategy should be compared with combination chemotherapy, the current standard of care.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.8494

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citation
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citation

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 201–300 of 830

EGFR inhibition in the treatment of non‐small cell lung cancer
Gerber, D. E. (2008) · Drug Development Research · doi:10.1002/ddr.20268 · Cited by 70
Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma
Hsu, J., Huang, M., Chen, C., Liu, G., Liu, T., Chong, I., Chou, S., & Yang, C. (2014) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000116 · Cited by 70
Personalized Targeted Therapy for Lung Cancer
Wu, K., House, L. K., Liu, W., & Cho, W. C. S. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911471 · Cited by 71
Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases
Vendetti, F. P., & Rudin, C. M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.819337 · Cited by 68
Quantum dots in cancer therapy
Luo, G., Long, J., Zhang, B., Liu, C., Ji, S., Xu, J., Yu, X., & Ni, Q. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.638624 · Cited by 68
The “Lazarus Response” in Treatment-Naïve, Poor Performance Status Patients With Non–Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation
Langer, C. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4859 · Cited by 68
What’s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements
Cooper, W. A., O'Toole, S. A., Boyer, M. J., Horvath, L. G., & Mahar, A. M. (2011) · Pathology · doi:10.1097/pat.0b013e328342629d · Cited by 67
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503
Amann, J. M., Lee, J., Röder, H., Brahmer, J. R., González, A., Schiller, J. H., & Carbone, D. P. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c8cbd9 · Cited by 66
EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors
Sartori, G., Cavazza, A., Sgambato, A., Marchioni, A., Barbieri, F., Longo, L., Bavieri, M., Murer, B., Meschiari, E., Tamberi, S., et al. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcph0trmpxvzw2f · Cited by 66
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 67
Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells
Han, S., Zhao, M.-B., Zhuang, G.-B., & Li, P.-P. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.001 · Cited by 65
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110
Schulte, A., Liffers, K., Kathagen, A., Riethdorf, S., Zapf, S., Merlo, A., Kolbe, K., Westphal, M., & Lamszus, K. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not093 · Cited by 65
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
Linking somatic genetic alterations in cancer to therapeutics
Stuart, D. D., & Sellers, W. R. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.001 · Cited by 66
Apoptosis In Targeted Therapy Responses
Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 63
Self-citation
Gefitinib
Sanford, M., & Scott, L. J. (2009) · Drugs · doi:10.2165/10489100-000000000-00000 · Cited by 60
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
Kaira, K., Naito, T., Takahashi, T., Ayabe, E., Shimoyama, R., Kaira, R., Ono, A., Igawa, S., Shukuya, T., Murakami, H., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.006 · Cited by 61
Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer
Yang, X., Bai, F., Xu, Y., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000481754 · Cited by 63
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer
Steuer, C. E., Khuri, F. R., & Ramalingam, S. S. (2014) · Cancer · doi:10.1002/cncr.29139 · Cited by 62
Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
Campo, M. J., Al-Halabi, H., Khandekar, M. J., Shaw, A. T., Sequist, L. V. D., & Willers, H. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0508 · Cited by 65
Self-citation
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation
Chung, C., & Christianson, M. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212474047 · Cited by 62
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
Okamoto, I., Takahashi, T., Okamoto, H., Nakagawa, K., Watanabe, K., Nakamatsu, K., Nishimura, Y., Fukuoka, M., & Yamamoto, N. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.016 · Cited by 61
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
Doebele, R. C., Oton, A. B., Peled, N., Camidge, D. R., & Bunn, P. A. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.12.009 · Cited by 62
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
Marcar, L., Bardhan, K., Gheorghiu, L., Dinkelborg, P. H., Pfäffle, H. N., Liu, Q., Wang, M., Piotrowska, Z., Sequist, L. V. D., Borgmann, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.058 · Cited by 63
Self-citation
Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
Zhong, J., Li, L., Wang, Z., Bai, H., Gai, F., Duan, J., Zhao, J., Zhuo, M., Wang, Y., Wang, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.032 · Cited by 61
Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations
Yang, J., Wang, L., Liu, J., Zhong, L., Zheng, R., Xu, Y., Ji, P., Zhang, C., Wang, W., Lin, X., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301365e · Cited by 59
Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice
Lam, Y. W. F. (2013) · ISRN Pharmacology · doi:10.1155/2013/641089 · Cited by 61
Continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer.
Bruera, E. D., Brenneis, C., Michaud, M., Chadwick, S., & MacDonald, R. N. (1987) · PubMed · Cited by 59
Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway
Han, Z., Zhou, X., Li, S., Qin, Y., Chen, Y., & Liu, H. (2017) · Oncology Reports · doi:10.3892/or.2017.5938 · Cited by 58
IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype
Cadranel, J. L., Quoix, É., Baudrin, L., Mourlanette, P., Moro‐Sibilot, D., Morère, J., Souquet, P.-J., Soria, J., Morin, F., & Milleron, B. J. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181abeb5d · Cited by 58
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer
Hainsworth, J. D., Fang, L., Huang, J. E., Karlin, D. A., Russell, K., Faoro, L. N., & Azzoli, C. G. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f94ad4 · Cited by 58
Second‐line treatments after first‐line gefitinib therapy in advanced nonsmall cell lung cancer
Wu, J., Shih, J., Yang, C., Chen, K., Ho, C., Yu, C., & Yang, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24657 · Cited by 58
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
Scarborough, H. A., Helfrich, B. A., Casás‐Selves, M., Schuller, A. G., Grosskurth, S. E., Kim, J., Tan, A. C., Chan, D. C. F., Zhang, Z., Zaberezhnyy, V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1179 · Cited by 57
Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older
Chen, Y.-M., Tsai, C., Fan, W.-C., Shih, J.-F., Liu, S.-H., Wu, C.-H., Chou, T., Lee, Y.-C., Perng, R.-P., & Whang‐Peng, J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823a39e8 · Cited by 57
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
Chang, Y. S., Choi, C., & Lee, J. C. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.4.248 · Cited by 59
Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells
Russo, V. M., Paciocco, A., Affinito, A., Roscigno, G., Fiore, D., Palma, F., Galasso, M., Volinia, S., Fiorelli, A., Esposito, C. L., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.016 · Cited by 58
Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., Nakamura, T., & Yamamoto, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7340 · Cited by 59
Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Cell Lung Carcinoma [ERMETIC] Project—Part 1)
Beau‐Faller, M., Degeorges, A., Rolland, E., Mounawar, M., Antoine, M., Poulot, V., Mauguen, A., Barbu, V., Coulet, F., Prétet, J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318211dcee · Cited by 56
Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy
Ardini, E., Magnaghi, P., Orsini, P., Galvani, A. P., & Menichincheri, M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.09.001 · Cited by 58
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
Wu, Y.-L. L. C., Saijo, N., Thongprasert, S., Yang, J. C., Han, B., Margono, B. P., Chewaskulyong, B., Sunpaweravong, P., Ohe, Y., Ichinose, Y., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.022 · Cited by 57
Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer
Ye, M., Zhang, Y., Zhang, X., Zhang, J., Jing, P., Cao, L., Li, N., Li, X., Yao, L., Zhang, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3470 · Cited by 56
Computational analysis of next generation sequencing data and its applications in clinical oncology
Wadapurkar, R. M., & Vyas, R. (2018) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2018.05.003 · Cited by 60
Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain
Rosell, R., Morán, T., Carcereny, E., Quiroga, V., Molina‐Vila, M. Á., Costa, C., Benlloch, S., & Tarón, M. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0473-0 · Cited by 58
Gefitinib for the treatment of non-small-cell lung cancer
Hida, T., Ogawa, S., Park, J. C., Park, J. Y., Shimizu, J., Horio, Y., & Yoshida, K. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.1.17 · Cited by 58
EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non–Small Cell Lung Cancer Patients
Choi, Y. W., Jeon, S. Y., Jeong, G. S., Lee, H. W., Jeong, S. H., Kang, S. Y., Park, J. S., Choi, J.-H., Koh, Y. W., Han, J. H., et al. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000282 · Cited by 55
Personalized Medicine for Targeted and Platinum-Based Chemotherapy of Lung and Bladder Cancer
Cimino, G. D., Pan, C.-X., & Henderson, P. T. (2013) · Bioanalysis · doi:10.4155/bio.12.325 · Cited by 58
Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
Dienstmann, R., Martínez, P., & Felip, E. (2011) · Oncotarget · doi:10.18632/oncotarget.245 · Cited by 54
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells
Chiu, H.-C., Chou, D.-L., Huang, C.-T., Lin, W., Lien, T., Yen, K.-J., & Hsu, J. T.-A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.003 · Cited by 56
Emergency medical genomes: a breakthrough application of precision medicine
Kingsmore, S. F., Petrikin, J. E., Willig, L. K., & Guest, E. M. (2015) · Genome Medicine · doi:10.1186/s13073-015-0201-z · Cited by 53
Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI
Nishino, M., Dahlberg, S. E., Cardarella, S., Jackman, D. M., Rabin, M. S., Hatabu, H., Janne, P. A., & Johnson, B. E. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318294c909 · Cited by 53
Self-citation
Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
Chin, T. M., Quinlan, M. P., Singh, A., Sequist, L. V. D., Lynch, T. J., Haber, D. A., Sharma, S. V., & Settleman, J. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0093 · Cited by 53
Self-citation
The Landscape of EGFR Pathways and Personalized Management of Non-Small-Cell Lung Cancer
Liang Cheng, C., Zhang, S., Alexander, R. E., Yao, Y., MacLennan, G. T., Pan, C.-X., Huang, J., Wang, M., Montironi, R., & Antonio Lopez-beltran, B. (2011) · Future Oncology · doi:10.2217/fon.11.25 · Cited by 53
Targeted Therapy for Squamous Cell Lung Cancer
Liao, R. G., Watanabe, H., Meyerson, M. M., & Hammerman, P. S. (2012) · Lung Cancer Management · doi:10.2217/lmt.12.40 · Cited by 52
EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer
Wu, M., Zhao, J., Song, S. W., Zhuo, M., Wang, X., Bai, H., Wang, S., Yang, L., An, T., Zhang, Y., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.011 · Cited by 51
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Tiseo, M. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6594 · Cited by 51
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications
Ocak, S., Sos, M. L., Thomas, R. K., & Massion, P. P. (2009) · European Respiratory Journal · doi:10.1183/09031936.00042409 · Cited by 53
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma
Lin, G., Li, C., Li, P. S., Fang, W. Z., Xu, H., Gong, Y. H., Zhu, Z., Hu, Y., Liang, W., Chu, Q., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.014 · Cited by 51
An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer
Pezaro, C. J., Rosenthal, M. A., Gurney, H., Davis, I. D., Underhill, C. R., Boyer, M. J., Kotasek, D., Solomon, B., & Toner, G. C. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31818b946b · Cited by 51
CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis
Cheng, Z., Shan, F., Yang, Y., Shi, Y., & Zhang, Z. (2017) · BMC Medical Imaging · doi:10.1186/s12880-016-0175-3 · Cited by 52
Clinical Implications of MET Gene Copy Number in Lung Cancer
Toschi, L., & Cappuzzo, F. (2010) · Future Oncology · doi:10.2217/fon.09.164 · Cited by 54
RNA is favourable for analysingEGFRmutations in malignant pleural effusion of lung cancer
Tsai, T.-H., Su, K., Wu, S., Chang, Y., Luo, S., Jan, I., Yu, C., Yu, S.-L., Shih, J.-Y., & Yang, P. (2011) · European Respiratory Journal · doi:10.1183/09031936.00043511 · Cited by 50
Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy
Koh, Y. W., & Lee, H. W. (2017) · Medicine · doi:10.1097/md.0000000000006848 · Cited by 50
MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines
Zhou, Y., Liu, J., & Sun, W. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.3.1391 · Cited by 49
EGFR mutations in non‐small‐cell lung cancer among smokers and non‐smokers: A meta‐analysis
Ren, J., He, W., Yan, G., Jin, M., Yang, K., & Wu, G. (2011) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20680 · Cited by 49
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
Mendell, J., Freeman, D. J., Feng, W., Hettmann, T., Schneider, M. B., Blum, S., Ruhe, J. E., Bange, J., Nakamaru, K., Chen, S., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.005 · Cited by 49
Drug–Drug Molecular Salt Hydrate of an Anticancer Drug Gefitinib and a Loop Diuretic Drug Furosemide: An Alternative for Multidrug Treatment
Thorat, S. H., Sahu, S. K., Patwadkar, M. V., Badiger, M. V., & Gonnade, R. G. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24651 · Cited by 49
EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing
Lettig, L., Sahnane, N., Pepe, F., Cerutti, R., Albeni, C., Franzi, F., Veronesi, G., Ogliari, F. R., Pastore, A., Tuzi, A., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.18 · Cited by 51
Chemotherapy for lung cancer: the state of the art in 2009
Higgins, M. J., & Ettinger, D. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.115 · Cited by 49
Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis
Chen, Y., Wang, M., Zhong, W., & Zhao, J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.013 · Cited by 48
Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa™)
Langhammer, S., Koban, R., Yue, C., & Ellerbrok, H. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.11.006 · Cited by 48
Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non–Small Cell Lung Cancer: A Phase I Trial
Rothschild, S. I., Bucher, S. E., Bernier, J., Aebersold, D. M., Zouhair, A., Ries, G., Lombrieser, N., Lippuner, T., Lütolf, U. M., Glanzmann, C., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.048 · Cited by 48
Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment
Moran, C. A. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.057 · Cited by 46
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer
Brzezniak, C. E., Carter, C. A., & Giaccone, G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.758714 · Cited by 48
Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice
Hinrichs, J. W. J., van Blokland, W. T. M., Moons, M. J., Radersma, R. D., Loon, J. H. R., de Voijs, C. M. A., Rappel, S. B., Koudijs, M. J., Besselink, N. J. M., Willems, S. M., et al. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp40xetvyamjpy · Cited by 47
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
Wang, H., Huang, J., Yu, X., Han, S., Yan, X., Sun, S., & Zhu, X. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1709-0 · Cited by 47
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
Rosell, R., Viteri, S., Molina‐Vila, M. Á., Benlloch, S., & Tarón, M. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833500d2 · Cited by 45
Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China
Wu, Y.-L. L. C., Chu, D.-T., Han, B., Liu, X., Zhang, L., Zhou, C., Liao, M., Mok, T. S. K., Jiang, H., Duffield, E. L., et al. (2012) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2012.01518.x · Cited by 47
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle
Patel, H., Pawara, R. H., Ansari, A., Noolvi, M. N., & Surana, S. J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.039 · Cited by 47
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
Pilotto, S., Rossi, A., Vavalà, T., Follador, A., Tiseo, M., Galetta, D., Morabito, A., Di Maio, M., Martelli, O., Caffo, O., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.016 · Cited by 46
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Nanni, C., Boschi, S., Lodi, F., Nicoletti, G., Landuzzi, L., Lollini, P., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn625 · Cited by 45
Tissue-Agnostic Drug Development
Flaherty, K. T., Le, D. T., & Lemery, S. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_173855 · Cited by 47
Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI
Ma, Y., Pan, X., Xu, P., Mi, Y., Wang, W., Wu, X., He, Q., Liu, X., Tang, W., & An, H. (2017) · Oncotarget · doi:10.18632/oncotarget.19874 · Cited by 46
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications
Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44
Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations
Morán, T., & Sequist, L. V. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1858 · Cited by 44
Self-citation
Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes
Han, S., Zhao, H., Zhou, N., Zhou, F., & Li, P. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.10.021 · Cited by 44
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
Metro, G., & Crinò, L. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.34 · Cited by 45
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer
West, H., Lilenbaum, R., Harpole, D. H., Wozniak, A. J., & Sequist, L. V. D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b27170 · Cited by 44
Self-citation
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application
Lee, S., & McLeod, H. L. (2010) · The Journal of Pathology · doi:10.1002/path.2766 · Cited by 44
The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
Kwak, E. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0087 · Cited by 44
Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors
Bertotti, A., Bracco, C., Girolami, F., Torti, D., Gastaldi, S., Galimi, F., Medico, E., Elvin, P., Comoglio, P., & Trusolino, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0106 · Cited by 47
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
Wang, J., Li, X., Xue, X., Ou, Q., Wu, X., Liang, Y., Wang, X., You, M., Shao, Y. W., Zhang, Z., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31895 · Cited by 44
Redox-responsive hyaluronic acid-functionalized graphene oxide nanosheets for targeted delivery of water-insoluble cancer drugs
Liu, J., Zhang, D., Lian, S., Zheng, J., Li, B., Li, T., & Jia, L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s173889 · Cited by 44
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Burtness, B. A., & Faller, B. A. (2009) · Biologics · doi:10.2147/btt.2009.3546 · Cited by 44
Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain
Petrulli, J. R., Sullivan, J. M., Zheng, M., Bennett, D. C., Charest, J., Huang, Y. H., Morris, E. D., & Contessa, J. N. (2013) · Neoplasia · doi:10.1593/neo.131666 · Cited by 43
EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer
Weber, B., Hager, H., Sørensen, B. S., McCulloch, T., Mellemgaard, A., Khalil, A. A., Nexø, E., & Meldgaard, P. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.023 · Cited by 43
RET inhibition: implications in cancer therapy
Borrello, M. G., Ardini, E., Locati, L. D., Greco, A., Licitra, L. F., & Pierotti, M. A. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.758715 · Cited by 43

Authors: Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., & Lynch, T. J.
Affiliations: Brigham and Women's Hospital (US)
From the Massachusetts General Hospital Cancer Center; Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital; Department of Pathology, Massachusetts General Hospital; Department of Biostatistics, Massachusetts General Hospital, Boston; Harvard Medical School/Partners Health Care Center for Genetics and Genomics, Cambridge, MA; University of Washington, Seattle, WA; Sarah Cannon Research Institute, Nashville, TN; Fletcher Allen Health Care, Burlington, VT; Fairfax-Northern...
ORCID: Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Spira, Alexander
Evans, Tracey L.
Muzikansky, Alona
Han, Moon
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2442-2449
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.8494
OpenAlex: W2101329867
Cited by: 820
References: 46
Citations by year: 2026: 4 · 2025: 14 · 2024: 9 · 2023: 11 · 2022: 20 · 2021: 22 · 2020: 34 · 2019: 29 · 2018: 51 · 2017: 51 · 2016: 54 · 2015: 57 · 2014: 68 · 2013: 69 · 2012: 60
FWCI: 81.10
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, non-small cell lung cancer, EGFR mutation, first-line therapy, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, T790M mutation, MET amplification, progression-free survival, response rate, pneumonitis, genotype-directed therapy
MeSH terms: Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prospective Studies, Quinazolines, Survival Rate, Central Nervous System Neoplasms, Treatment Outcome, In Situ Hybridization, Fluorescence, Carcinoma, Large Cell, Disease-Free Survival, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks